{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T12:57:58Z","timestamp":1774097878730,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1053\/j.seminhematol.2015.04.001","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T22:54:01Z","timestamp":1428620041000},"page":"184-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia"],"prefix":"10.1053","volume":"52","author":[{"given":"Peter","family":"Hokland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans B.","family":"Ommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Mul\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.seminhematol.2015.04.001_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.12419","article-title":"Readying the minimal residual disease concept in acute myeloid leukaemia for prime time\u2014the American way","volume":"162","author":"Hokland","year":"2013","journal-title":"Br J Haematol."},{"issue":"23","key":"10.1053\/j.seminhematol.2015.04.001_bib2","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","article-title":"Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \"prime time\"?","volume":"124","author":"Grimwade","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2015.04.001_bib3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2012.09203.x","article-title":"Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission\u2014methodologies in relation to their clinical situation","volume":"158","author":"Hokland","year":"2012","journal-title":"Br J Haematol."},{"issue":"9","key":"10.1053\/j.seminhematol.2015.04.001_bib4","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/blood-2010-09-303685","article-title":"Towards individualized follow-up in adult acute myeloid leukemia in remission","volume":"117","author":"Hokland","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.13048","article-title":"Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age","volume":"167","author":"Roug","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2015.04.001_bib6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","article-title":"Minimal residual disease in acute myeloid leukaemia","volume":"10","author":"Hourigan","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/asheducation.V2012.1.35.3797926","article-title":"Minimal residual disease in acute myeloid leukemia: coming of age","volume":"2012","author":"Paietta","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MOH.0b013e32835dd90a","article-title":"Should evaluation for minimal residual disease be routine in acute myeloid leukemia?","volume":"20","author":"Coustan-Smith","year":"2013","journal-title":"Curr Opin Hematol"},{"issue":"15","key":"10.1053\/j.seminhematol.2015.04.001_bib9","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2014-11-578815","article-title":"Minimal residual disease-directed therapy in acute myeloid leukemia","volume":"125","author":"Kayser","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2015.04.001_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2013.10.008","article-title":"Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia","volume":"26","author":"Appelbaum","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"22","key":"10.1053\/j.seminhematol.2015.04.001_bib11","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2015.04.001_bib12","doi-asserted-by":"crossref","first-page":"e1004462","DOI":"10.1371\/journal.pgen.1004462","article-title":"Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing","volume":"10","author":"Hughes","year":"2014","journal-title":"PLoS Genet"},{"issue":"3","key":"10.1053\/j.seminhematol.2015.04.001_bib13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","article-title":"Functional heterogeneity of genetically defined subclones in acute myeloid leukemia","volume":"25","author":"Klco","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1053\/j.seminhematol.2015.04.001_bib14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/leu.2014.14","article-title":"Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues","volume":"28","author":"Goswami","year":"2014","journal-title":"Leukemia"},{"issue":"7382","key":"10.1053\/j.seminhematol.2015.04.001_bib15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"12","key":"10.1053\/j.seminhematol.2015.04.001_bib17","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u05f3real-time\u05f3 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2015.04.001_bib18","first-page":"1267","article-title":"Quantification of DEK-CAN fusion transcript by real-time reverse transcription polymerase reaction in patients with t(6;9) acute myeloid leukemia","volume":"89","author":"Tobal","year":"2004","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2015.04.001_bib20","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1038\/sj.leu.2402675","article-title":"Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients","volume":"16","author":"Cilloni","year":"2002","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2015.04.001_bib21","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood.V84.9.3071.3071","article-title":"WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia","volume":"84","author":"Inoue","year":"1994","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/1078-0432.CCR-14-1999","article-title":"Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia","volume":"21","author":"Steinbach","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/bmt.2014.326","article-title":"A multigene array for measurable residual disease detection in AML patients undergoing SCT","author":"Goswami","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1053\/j.seminhematol.2015.04.001_bib24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.bbmt.2014.07.002","article-title":"Next Generation MRD","volume":"20","author":"Hourigan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1053\/j.seminhematol.2015.04.001_bib25","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","article-title":"Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival","volume":"20","author":"Logan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1053\/j.seminhematol.2015.04.001_bib26","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/leu.2013.52","article-title":"Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia","volume":"27","author":"Logan","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2015.04.001_bib27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.21955","article-title":"Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations","volume":"51","author":"Thol","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib28","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.23696","article-title":"Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA","volume":"89","author":"Duployez","year":"2014","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2015.04.001_bib30","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","author":"Mailankody","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1053\/j.seminhematol.2015.04.001_bib32","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2015.04.001_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/asheducation-2014.1.244","article-title":"Detection and management of minimal residual disease in acute lymphoblastic leukemia","volume":"2014","author":"Schrappe","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"214","key":"10.1053\/j.seminhematol.2015.04.001_bib34","doi-asserted-by":"crossref","first-page":"214ra171","DOI":"10.1126\/scitranslmed.3007420","article-title":"Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma","volume":"5","author":"Weng","year":"2013","journal-title":"Sci Transl Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2015.04.001_bib35","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-13-3231","article-title":"Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH","volume":"20","author":"Wu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"134","key":"10.1053\/j.seminhematol.2015.04.001_bib36","doi-asserted-by":"crossref","first-page":"134ra163","DOI":"10.1126\/scitranslmed.3003656","article-title":"High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia","volume":"4","author":"Wu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2015.17","article-title":"Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing","author":"Young","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2015.04.001_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrg3655","article-title":"The role of replicates for error mitigation in next-generation sequencing","volume":"15","author":"Robasky","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"49","key":"10.1053\/j.seminhematol.2015.04.001_bib39","doi-asserted-by":"crossref","first-page":"19872","DOI":"10.1073\/pnas.1319590110","article-title":"High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing","volume":"110","author":"Lou","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1053\/j.seminhematol.2015.04.001_bib40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.13062","article-title":"Persistence of DNMT3A mutations at long-term remission in adult patients with AML","volume":"167","author":"Ploen","year":"2014","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2015.04.001_bib41","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2015.04.001_bib42","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2015.04.001_bib43","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2015.04.001_bib44","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"issue":"7","key":"10.1053\/j.seminhematol.2015.04.001_bib45","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"149","key":"10.1053\/j.seminhematol.2015.04.001_bib46","doi-asserted-by":"crossref","first-page":"149ra118","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fonc.2014.00078","article-title":"Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics","volume":"4","author":"Pant","year":"2014","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2156-14-6","article-title":"Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations","volume":"14","author":"Chin","year":"2013","journal-title":"BMC Genet"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib49","doi-asserted-by":"crossref","first-page":"626","DOI":"10.5731\/pdajpst.2014.01024","article-title":"FDA\u05f3s Activities Supporting Regulatory Application of \"Next Gen\" Sequencing Technologies","volume":"68","author":"Wilson","year":"2014","journal-title":"PDA J Pharm Sci Technol"},{"issue":"12","key":"10.1053\/j.seminhematol.2015.04.001_bib50","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2015.04.001_bib51","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.leukres.2005.08.030","article-title":"Minimal residual core binding factor AMLs by real time quantitative PCR\u2014initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse","volume":"30","author":"Stentoft","year":"2006","journal-title":"Leuk Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib52","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2141.2008.07132.x","article-title":"Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals","volume":"141","author":"Ommen","year":"2008","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2015.04.001_bib53","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3324\/haematol.2009.007765","article-title":"Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation","volume":"94","author":"Bornhauser","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib54","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood-2009-04-212530","article-title":"Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias","volume":"115","author":"Ommen","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2015.04.001_bib55","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3324\/haematol.2011.044388","article-title":"Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse","volume":"96","author":"Sockel","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2015.04.001_bib56","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjh.12792","article-title":"Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene","volume":"165","author":"Ommen","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2015.04.001_bib57","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12511","article-title":"The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients","author":"Ommen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2015.04.001_bib59","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2015.04.001_bib60","first-page":"1422","article-title":"Risk-adapted, MRD-refined therapeutic approach for the treatment of acute myeloid leukemia: from a single center experience to the Cooperative Gimema Protocol AML1310","volume":"120","author":"Venditti","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"7","key":"10.1053\/j.seminhematol.2015.04.001_bib61","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/leu.2011.69","article-title":"Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet","volume":"25","author":"Ostergaard","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib62","doi-asserted-by":"crossref","DOI":"10.1007\/s11096-010-9462-1","article-title":"Induction-related cost of patients with acute myeloid leukaemia in France","volume":"33","author":"Nerich","year":"2011","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"10.1053\/j.seminhematol.2015.04.001_bib63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.leukres.2012.09.018","article-title":"The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands","volume":"37","author":"Leunis","year":"2013","journal-title":"Leuk Res"},{"issue":"20","key":"10.1053\/j.seminhematol.2015.04.001_bib64","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1002\/cncr.26095","article-title":"Acute myeloid leukemia","volume":"117","author":"Bradley","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1053\/j.seminhematol.2015.04.001_bib65","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamainternmed.2014.2302","article-title":"Variation in inpatient costs of hematopoietic cell transplantation among transplant centers in the United States","volume":"174","author":"Thao","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2015.04.001_bib66","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2012-05-426783","article-title":"Economics of hematopoietic cell transplantation","volume":"120","author":"Khera","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib67","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3111\/13696998.2013.791301","article-title":"Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Sanchez-Ortega","year":"2013","journal-title":"J Med Econ"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2015.04.001_bib69","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bbmt.2005.04.004","article-title":"Evaluation and automation of hematopoietic chimerism analysis based on real-time quantitative polymerase chain reaction","volume":"11","author":"Masmas","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib70","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nbt0214-115a","article-title":"Illumina claims $1,000 genome win","volume":"32","author":"Sheridan","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"14","key":"10.1053\/j.seminhematol.2015.04.001_bib71","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2010-05-285387","article-title":"Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm","volume":"116","author":"Walter","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib72","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbmt.2013.11.017","article-title":"Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation","volume":"20","author":"Hourigan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1053\/j.seminhematol.2015.04.001_bib73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0145-2126(02)00166-2","article-title":"Modeling minimal residual disease (MRD)-testing","volume":"27","author":"Butturini","year":"2003","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib74","first-page":"676","article-title":"Criteria for the evaluation of response to treatment in acute leukemia","volume":"11","author":"Bisel","year":"1956","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib75","first-page":"500","article-title":"The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia","volume":"53","author":"Zeleznikova","year":"2006","journal-title":"Neoplasma"},{"issue":"31","key":"10.1053\/j.seminhematol.2015.04.001_bib76","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2015.04.001_bib77","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2015.04.001_bib78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib79","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib80","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1309\/FY0UMAMM91VPMR2W","article-title":"Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry","volume":"129","author":"Al-Mawali","year":"2008","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1053\/j.seminhematol.2015.04.001_bib81","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.seminhematol.2014.08.004","article-title":"Mutation position within evolutionary subclonal architecture in AML","volume":"51","author":"Welch","year":"2014","journal-title":"Semin Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2015.04.001_bib82","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood-2002-01-0195","article-title":"Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse","volume":"100","author":"Shih","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2015.04.001_bib83","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2002-02-0420","article-title":"Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors","volume":"100","author":"Kottaridis","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2015.04.001_bib84","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.2012.062638","article-title":"Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia","volume":"97","author":"Nazha","year":"2012","journal-title":"Haematologica"},{"issue":"13","key":"10.1053\/j.seminhematol.2015.04.001_bib85","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1073\/pnas.97.13.7521","article-title":"AML1\/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation","volume":"97","author":"Miyamoto","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1053\/j.seminhematol.2015.04.001_bib86","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1182\/blood.V87.11.4789.bloodjournal87114789","article-title":"Persistence of multipotent progenitors expressing AML1\/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia","volume":"87","author":"Miyamoto","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2015.04.001_bib87","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/sj.leu.2401133","article-title":"RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL","volume":"12","author":"Tobal","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2015.04.001_bib88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.1995.tb05592.x","article-title":"Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia","volume":"90","author":"Tobal","year":"1995","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib89","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3109\/10428194.2013.840776","article-title":"Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse","volume":"55","author":"Jain","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1053\/j.seminhematol.2015.04.001_bib90","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1600-0609.2011.01673.x","article-title":"NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression","volume":"87","author":"Kristensen","year":"2011","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2015.04.001_bib91","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2015.04.001_bib92","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2015.04.001_bib93","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3324\/haematol.2008.004267","article-title":"How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet","volume":"94","author":"Bene","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2015.04.001_bib94","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/ijlh.12193","article-title":"Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings","volume":"36","author":"Cui","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2015.04.001_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.20037","article-title":"Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring","volume":"63","author":"Langebrake","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1053\/j.seminhematol.2015.04.001_bib96","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.b.20025","article-title":"Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings","volume":"62","author":"Voskova","year":"2004","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1053\/j.seminhematol.2015.04.001_bib97","first-page":"26855","article-title":"Adult Acute Myeloid Leukemia Long-term Survivors","volume":"2","author":"Cheng","year":"2014","journal-title":"J Leuk (Los Angel)"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.23988","article-title":"The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia","author":"Ouyang","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2015.04.001_bib99","unstructured":"http:\/\/www.fda.gov\/Drugs\/NewsEvents\/ucm341421.htm. \"Public Workshop on Minimal Residual Disease (MRD) as a Surrogate Endpoint in Acute Myeloid Leukemia (AML).\" March 4th, 2013. http:\/\/www.fda.gov\/Drugs\/NewsEvents\/ucm341421.htm: FDA; 2013."},{"issue":"5","key":"10.1053\/j.seminhematol.2015.04.001_bib100","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/leu.2013.318","article-title":"What does MRD in leukemia really mean?","volume":"28","author":"Goldman","year":"2014","journal-title":"Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196315000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196315000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:24:14Z","timestamp":1758522254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196315000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0037196315000372"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2015.04.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2015.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}